The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

The availability of weight loss drugs on the NHS doesn’t mean people can give up healthy lifestyles, Health Secretary Wes Streeting has warned. Experts believe drugs like Ozempic will play an ...

The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Prescription drugs such as Ozempic, WeGovy, and Mounjaro have gained popularity as game changers due to their ability to ...